ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2763

Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease

Shunsei Hirohata1, Hirotoshi Kikuchi2, Tetsuji Sawada3, Hiroko Nagafuchi4, Msataka Kuwana5, Mitsuhiro Takeno6 and Yoshiaki Ishigatsubo7, 1Int Med/Rheumatol & Infec Dis, Kitasato Univ School of Med, Kanagawa, Japan, 2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 3Internal Medicine 3, Tokyo Medical University, Tokyo, Japan, 4Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, 5Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 6Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan, 7Int Med & Clin Immunology, Yokohama City Grad Schl of Med, Yokohama, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, central nervous system involvement, infliximab, methotrexate (MTX) and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chronic progressive neurological manifestations in Behcet’s disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous attacks, thus called chronic progressive neuro-Behcet’s disease (CPNBD). Although high doses of steroids, including steroid pulse therapy, cyclophosphamide and azathioprine have been anecdotally used in the treatment of CPNBD, the prognosis of the patients treated with such drugs have been usually miserable. Notably, methotrexate has been found effective for CPNBD in a prospective open trial with a small number of patients. However, its influences on the long-term outcome in a larger population remain unclear. The present study was designed to explore the effects of various treatment regimens, including methotrexate, on the prognosis of patients with CPNBD.

Methods: Thirty-seven patients, who met the international classification criteria for BD, and developed chronic progressive manifestations of NBD after 1988, were followed up until October 2013. The effects of various treatment regimens on prevention of death or severe disability of bedridden state were examined by Kaplan-Meier analysis and Cox’s proportional hazard model.

Results: In 37 patients with CPNBD, 28 patients (75.7%) received methotrexate. Among the 28 patients with methotrexate, no patients died and only 5 patients progressed to disability with bedridden state. By contrast, among the 9 patients without methotrexate, 5 patients died and 3 patients progressed to the bedridden state. Thus, methotrexate significantly improved the survival of patients with CPNBD (HR 0.0507, 95% CI: 0.0077-0.334, p=0.020 as calculated by Mantel-Cox test) (figure), but any of steroid pulse, azathioprine or cyclophosphamide did not. Methotrexate also significantly reduced the proportion of the patients who were progressed into the bedridden state or death (HR 0.0694, 95% CI: 0.0047-0.7327, p=0.0258 as determined by multivariate analysis in Cox proportional hazard model).

Conclusion: These results indicate that methotrexate, but not high doses of steroids, azathioprine or cyclophosphamide, is effective to prevent the progression of CPNBD. Thus, it is recommended that methotrexate should be started as soon as possible the diagnosis of CPNBD is made.

Software: Office ããã<font face=g°³�”>


Disclosure:

S. Hirohata,
None;

H. Kikuchi,
None;

T. Sawada,
None;

H. Nagafuchi,
None;

M. Kuwana,
None;

M. Takeno,
None;

Y. Ishigatsubo,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-outcome-of-chronic-progressive-neurological-manifestations-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology